GlassScriptPhysician profile
Craig H Lundgren
NPI 1508820655
$10,730.91
in general payments reported to CMS, 2019-2025
43 companies · $1,971 in 2025
The $1,971 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,595 · 2020: $780 · 2021: $1,285 · 2022: $1,681 · 2023: $2,030 · 2024: $1,389 · 2025: $1,971.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,389.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,324.27 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $1,187.42 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,176.54 | 2019-2025 | |
| Boston Scientific Corporation | $1,105.83 | 2020-2025 | Watchman Flx, Watchman Access System, Versacross Access Solution |
| E.R. Squibb & Sons, L.L.C. | $859.97 | 2019-2025 | Eliquis, Camzyos |
| Sanofi-Aventis U.S. LLC | $680.04 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $522.28 | 2019-2024 | Xarelto |
| Abbott Laboratories | $430.15 | 2019-2025 | Cardiomems, Amplatzer Amulet |
| Kowa Pharmaceuticals America, INC. | $379.25 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $359.74 | 2019-2025 | Andexxa, Farxiga |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $282.02 | 2023-2025 | Lifevest |
| Novo Nordisk INC | $245.17 | 2024-2025 | Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $214.85 | 2022-2023 | |
| Actelion Pharmaceuticals US, INC. | $208.54 | 2021-2024 | Opsumit, Uptravi |
| Bridgebio Pharma, INC. | $193.36 | 2025 | Attruby |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Lundgren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.